Works by Zimmermann, Annamaria
Results: 9
Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non--Small-Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2014, v. 15, n. 6, p. 418, doi. 10.1016/j.cllc.2014.06.007
- By:
- Publication type:
- Article
Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer.
- Published in:
- Current Medical Research & Opinion, 2020, v. 36, n. 10, p. 1667, doi. 10.1080/03007995.2020.1808781
- By:
- Publication type:
- Article
Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.
- Published in:
- Cancer (0008543X), 2011, v. 117, n. 20, p. 4732, doi. 10.1002/cncr.26068
- By:
- Publication type:
- Article
East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)
- Published in:
- Cancer Research & Treatment, 2016, v. 48, n. 4, p. 1177, doi. 10.4143/crt.2015.401
- By:
- Publication type:
- Article
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 7, p. 3182, doi. 10.1111/bcp.15233
- By:
- Publication type:
- Article
Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY.
- Published in:
- Cancer Science, 2020, v. 111, n. 12, p. 4510, doi. 10.1111/cas.14655
- By:
- Publication type:
- Article